Sarcomatoid combined hepatocellular-cholangiocarcinoma is an extremely rare primary hepatic malignancy and only a few cases have been reported. Herein, we report a case of combined hepatocellular-cholangiocarcinoma with sarcomatoid changes in a 52-year-old man, who had a history of liver cirrhosis and transarterial chemoembolization. The resected liver revealed a mass of 4.5×3.5 cm. Microscopically, the tumor was composed of adenocarcinoma intermingled with poorly differentiated hepatocellular carcinoma, which contained atypical spindle cells. We also present a short review of reported cases of sarcomatoid combined hepatocellular-cholangiocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270511 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathologic and ultrasonographic features of combined hepatocellular-cholangiocarcinoma and its correlation with microvascular invasion: a predictive role of contrast-enhanced ultrasound.
Front Oncol
December 2024
Clinical Medical College, Guizhou Medical University, Guiyang, Guizhou, China.
Article Synopsis
- The study investigates the characteristics of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and its association with microvascular invasion (MVI) using ultrasonography, particularly contrast-enhanced ultrasound (CEUS).
- A retrospective analysis of 57 patients with cHCC-CCA found that those with MVI exhibited specific ultrasonographic features, such as larger tumor size and distinct CEUS patterns.
- Results indicated that features like low echo halo, irregular rim-like enhancement, and early washout are significant risk factors for MVI, providing a predictive tool for clinicians.
Reply to "Comment on 'Prognostic Impact of the Cholangiolar Component in Combined Hepatocellular-Cholangiocarcinoma: Insights From a Western Single-Center Study'".
J Surg Oncol
December 2024
Departament of Gastroenterology, Digestive Surgery Division, Liver Surgery Unit, University of São Paulo Medical School, São Paulo, Brazil.
Radiomics predicting immunohistochemical markers in primary hepatic carcinoma: Current status and challenges.
Heliyon
December 2024
Department of Intervention, Shenzhen People's Hospital, Shenzhen, 518020, Guangdong, China.
Primary hepatic carcinoma, comprising hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined hepatocellular cholangiocarcinoma (cHCC-CCA), ranks among the most common malignancies worldwide. The heterogeneity of tumors is a primary factor impeding the efficacy of treatments for primary hepatic carcinoma. Immunohistochemical markers may play a potential role in characterizing this heterogeneity, providing significant guidance for prognostic analysis and the development of personalized treatment plans for the patients with primary hepatic carcinoma.
View Article and Find Full Text PDFPersistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion.
Mol Cancer
December 2024
Key Laboratory of Birth Defects and Related Diseases of Women and Children, West China Second University Hospital, Ministry of Education, Sichuan University, Chengdu, 610041, Sichuan, P.R. China.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA), an extremely rare and underinvestigated subtype of primary liver cancer in children, generally has a poor prognosis and greater aggressiveness. Histological diagnosis of cHCC-CCA is difficult because of its diverse components, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). cHCC-CCA shares some genetic alterations with HCC and CCA.
View Article and Find Full Text PDFEstablishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma.
Hum Cell
December 2024
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a unique subtype of primary liver cancer displaying both hepatocytic and cholangiocytic differentiation. The development of effective treatments for cHCC-CCA remains challenging because of its high heterogeneity and lack of a suitable model system. Using a three-dimensional culture system, we successfully established two novel cHCC-CCA organoid lines from patients undergoing surgical resection for primary liver cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!